Home › Companies › CABALETTA BIO INC. › 2024-2025

CABALETTA BIO INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and CABALETTA BIO INC.’s Form 8-K, filed 2025-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
104Asset managers
980Fund votes
2025-06-09Meeting date

Proxy season: 2024-2025

Explore CABALETTA BIO INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by CABALETTA BIO INC.

These tallies are CABALETTA BIO INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CABALETTA BIO INC. — official shareholder meeting results, meeting held 2025-06-09
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Steven Nichtberger, M.D.	25,271,870	--	--	618,531	8,692,070	Majority: yes
Elect Director: Mark Simon, MBA	13,482,164	--	--	12,408,237	8,692,070	Majority: yes
The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, recommended for ratification in Proposal 2 at the Annual M	34,369,582	124,022	88,867	--	0	Majority: yes
The Company's stockholders approved the amendment to the Company's Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000, recommended for approval	32,584,702	1,962,883	34,886	--	0	Majority: yes
The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 4.	13,973,541	11,809,869	106,991	--	8,692,070	Majority: yes
Proposal 6: deemed not necessary because there was a quorum present and there were sufficient proxies at the time of the Annual Meeting to approve Proposal 3, it was approved by the requisite vote as follows:	29,020,998	5,409,536	151,937	--	0	Majority: yes

Source: CABALETTA BIO INC., Form 8-K, filed with the SEC on 2025-06-10 — read the filing on EDGAR.

How asset managers voted at the CABALETTA BIO INC. 2024-2025 meeting

Each item below shows how the 104 asset managers that disclosed a CABALETTA BIO INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CABALETTA BIO INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

54.2% Majority: yes · of votes cast

FOR 54.2%AGAINST 45.8%

FOR: 13,973,541AGAINST: 11,809,869

CABALETTA BIO INC.’s own tally for this item (“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 4.”): 13,973,541 for, 11,809,869 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,743,101 outstanding shares: 28% for, 23% against (50.8% of the company cast a for/against vote).

The 104 asset managers below cast 46.1% of the shares they voted on this item FOR (10,446,965 for, 12,210,061 against).

FOR 46.1%AGAINST 53.9%

FOR: 10,446,965 (46.1%)AGAINST: 12,210,061 (53.9%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at CABALETTA BIO INC., 2024-2025
Asset manager	For	Against	Vote
T. Rowe Price	39,770	5,926,493	Against
Bain Capital Life Sciences Investors, LLC	2,760,888	0	For
BlackRock	2,158,814	0	For
JENNISON ASSOCIATES LLC	1,845,391	0	For
Vanguard	0	1,836,962	Against
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	1,742,237	Against
Prudential/PGIM	905,354	0	For
Federated Hermes	653,247	6,238	For
GEODE CAPITAL MANAGEMENT, LLC	0	540,282	Against
State Street	452,243	3,454	For
Fidelity	0	423,518	Against
SUPERSTRING CAPITAL MANAGEMENT LP	367,981	0	For
Charles Schwab	0	319,732	Against
Raiffeisen Bank International AG	300,000	0	For
AXA INVESTMENT MANAGERS UK Ltd	0	270,271	Against
Two Sigma	0	267,636	Against
Northern Trust	256,177	1,387	For
Thrivent	0	188,207	Against
Integral Health Asset Management, LLC	153,245	0	For
Equitable	81,169	71,030	For
MELLON INVESTMENTS Corp	0	115,655	Against
TCG Crossover Management, LLC	86,795	0	For
AllianceBernstein	0	65,052	Against
QUANTITATIVE MASTER SERIES LLC	64,117	0	For
FRED ALGER MANAGEMENT, LLC	0	60,845	Against

Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.

2. NON-BINDING, ADVISORY VOTE ON THE FREQUENCY OF FUTURE NON-BINDING, ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

93% fund support · no official result

ONE YEAR 66%1 YEAR 31%

The 97 asset managers below cast 93% of the shares they voted on this item FOR (155,853 for, 12,352 against).

FOR: 155,853 (0.9%)AGAINST: 12,352 (0.1%)ONE YEAR: 11,704,134 (66.3%)1 YEAR: 5,491,245 (31.1%)2 YEARS: 300,000 (1.7%)THREE YEARS: 628 (0.0%)

Largest asset managers voting on “NON-BINDING, ADVISORY VOTE ON THE FREQUENCY OF FUTURE NON-BINDING, ADVISORY VOTES ON THE COMPENSATION OF OUR N” at CABALETTA BIO INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	0	One Year
BlackRock	0	1 Year
JENNISON ASSOCIATES LLC	0	1 Year
Vanguard	0	One Year
Prudential/PGIM	0	One Year
Federated Hermes	0	1 Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
State Street	0	One Year
Fidelity	0	One Year
Charles Schwab	0	1 Year
Raiffeisen Bank International AG	0	2 Years
AXA INVESTMENT MANAGERS UK Ltd	0	One Year
Two Sigma	0	One Year
Northern Trust	0	1 Year
Thrivent	0	One Year
Integral Health Asset Management, LLC	153,245	For
Equitable	0	One Year
MELLON INVESTMENTS Corp	0	One Year
AllianceBernstein	0	One Year
QUANTITATIVE MASTER SERIES LLC	0	1 Year
FRED ALGER MANAGEMENT, LLC	0	One Year
Nuveen	0	One Year
STIFEL NICOLAUS & CO INC \MO\	0	One Year
TIAA	0	One Year
Lincoln Financial	0	One Year

Showing the 25 largest of 97 asset managers. See all 97 in the interactive database.

3. To elect two class III directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Mark Simon, MBA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

52.1% Majority: yes · of votes cast

FOR 52.1%WITHHELD 47.9%

FOR: 13,482,164WITHHELD: 12,408,237

CABALETTA BIO INC.’s own tally for this item (“Elect Director: Mark Simon, MBA”): 13,482,164 for, 12,408,237 withheld, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,743,101 outstanding shares: 27% for, 24% withheld (51.0% of the company cast a for/withheld vote).

The 36 asset managers below cast 100% of the shares they voted on this item FOR (2,709,008 for, 0 against).

FOR 38%ABSTAIN 62%

FOR: 2,709,008 (38.5%)ABSTAIN: 4,333,195 (61.5%)

Largest asset managers voting on “To elect two class III directors to our board of directors, to serve until the 2028 annual meeting of stockhol” at CABALETTA BIO INC., 2024-2025
Asset manager	For	Abstain	Vote
T. Rowe Price	0	1,930,685	Abstain
Vanguard	1,767,721	0	For
BlackRock	0	905,056	Abstain
Prudential/PGIM	902,204	0	For
Fidelity	0	409,339	Abstain
Federated Hermes	0	321,176	Abstain
Charles Schwab	0	159,866	Abstain
Equitable	0	152,199	Abstain
Thrivent	0	92,880	Abstain
QUANTITATIVE MASTER SERIES LLC	0	64,117	Abstain
TIAA	0	39,686	Abstain
Northern Trust	0	36,626	Abstain
Lincoln Financial	34,200	0	For
AIG/SunAmerica	0	31,471	Abstain
Global X	0	26,547	Abstain
Pacific Life	0	22,121	Abstain
Nationwide	0	21,929	Abstain
John Hancock	0	20,425	Abstain
MASTER INVESTMENT PORTFOLIO	0	18,345	Abstain
Bridge Builder Trust	0	17,014	Abstain
Blackstone Alternative Investment Funds	0	11,200	Abstain
BRIDGEWAY FUNDS INC	0	10,862	Abstain
ProShares	0	9,135	Abstain
Goldman Sachs	0	7,909	Abstain
SEI	0	7,500	Abstain

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

4. To elect two class III directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Steven Nichtberger, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 25,271,870WITHHELD: 618,531

CABALETTA BIO INC.’s own tally for this item (“Elect Director: Steven Nichtberger, M.D.”): 25,271,870 for, 618,531 withheld, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,743,101 outstanding shares: 49.8% for, 1% withheld (51.0% of the company cast a for/withheld vote).

The 36 asset managers below cast 100% of the shares they voted on this item FOR (7,036,617 for, 0 against).

FOR 99.9%

FOR: 7,036,617 (99.9%)ABSTAIN: 5,586 (0.1%)

Largest asset managers voting on “To elect two class III directors to our board of directors, to serve until the 2028 annual meeting of stockhol” at CABALETTA BIO INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	1,930,685	For
Vanguard	1,767,721	For
BlackRock	905,056	For
Prudential/PGIM	902,204	For
Fidelity	409,339	For
Federated Hermes	321,176	For
Charles Schwab	159,866	For
Equitable	152,199	For
Thrivent	92,880	For
QUANTITATIVE MASTER SERIES LLC	64,117	For
TIAA	39,686	For
Northern Trust	36,626	For
Lincoln Financial	34,200	For
AIG/SunAmerica	31,471	For
Global X	26,547	For
Pacific Life	22,121	For
Nationwide	21,929	For
John Hancock	20,425	For
MASTER INVESTMENT PORTFOLIO	18,345	For
Bridge Builder Trust	17,014	For
Blackstone Alternative Investment Funds	11,200	For
BRIDGEWAY FUNDS INC	10,862	For
ProShares	9,135	For
Goldman Sachs	7,909	For
SEI	7,500	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

5. TO APPROVE A PROPOSAL TO ADJOURN THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY OR APPROPRIATE, TO PERMIT FURTHER SOLICITATION AND VOTE OF PROXIES IN THE EVENT THAT THERE ARE INSUFFICIENT VOTES FOR, OR OTHERWISE IN CONNECTION WITH, THE APPROVAL OF PROPOSAL 3.

CORPORATE GOVERNANCE

72% fund support · no official result

FOR 72%AGAINST 28%

The 36 asset managers below cast 72% of the shares they voted on this item FOR (5,056,196 for, 1,986,007 against).

FOR: 5,056,196 (71.8%)AGAINST: 1,986,007 (28.2%)

Largest asset managers voting on “TO APPROVE A PROPOSAL TO ADJOURN THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY OR APPROPRIATE, TO ” at CABALETTA BIO INC., 2024-2025
Asset manager	For	Against	Vote
T. Rowe Price	0	1,930,685	Against
Vanguard	1,767,721	0	For
BlackRock	905,056	0	For
Prudential/PGIM	902,204	0	For
Fidelity	409,339	0	For
Federated Hermes	321,176	0	For
Charles Schwab	159,866	0	For
Equitable	145,799	6,400	For
Thrivent	92,880	0	For
QUANTITATIVE MASTER SERIES LLC	64,117	0	For
TIAA	39,686	0	For
Northern Trust	36,626	0	For
Lincoln Financial	0	34,200	Against
AIG/SunAmerica	31,471	0	For
Global X	26,547	0	For
Pacific Life	22,121	0	For
Nationwide	21,929	0	For
John Hancock	10,638	9,787	For
MASTER INVESTMENT PORTFOLIO	18,345	0	For
Bridge Builder Trust	17,014	0	For
Blackstone Alternative Investment Funds	11,200	0	For
BRIDGEWAY FUNDS INC	10,862	0	For
ProShares	9,135	0	For
Goldman Sachs	7,909	0	For
SEI	7,500	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

6. TO APPROVE AN AMENDMENT TO OUR THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 150,000,000 TO 300,000,000.

CAPITAL STRUCTUREMajority of the votes cast: yes

94% Majority: yes · of votes cast

FOR 94%

FOR: 32,584,702AGAINST: 1,962,883

CABALETTA BIO INC.’s own tally for this item (“The Company's stockholders approved the amendment to the Company's Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000, reco”): 32,584,702 for, 1,962,883 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,743,101 outstanding shares: 64% for, 4% against (68% of the company cast a for/against vote).

The 36 asset managers below cast 100% of the shares they voted on this item FOR (7,042,203 for, 0 against).

FOR 100%

FOR: 7,042,203 (100.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER ” at CABALETTA BIO INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	1,930,685	For
Vanguard	1,767,721	For
BlackRock	905,056	For
Prudential/PGIM	902,204	For
Fidelity	409,339	For
Federated Hermes	321,176	For
Charles Schwab	159,866	For
Equitable	152,199	For
Thrivent	92,880	For
QUANTITATIVE MASTER SERIES LLC	64,117	For
TIAA	39,686	For
Northern Trust	36,626	For
Lincoln Financial	34,200	For
AIG/SunAmerica	31,471	For
Global X	26,547	For
Pacific Life	22,121	For
Nationwide	21,929	For
John Hancock	20,425	For
MASTER INVESTMENT PORTFOLIO	18,345	For
Bridge Builder Trust	17,014	For
Blackstone Alternative Investment Funds	11,200	For
BRIDGEWAY FUNDS INC	10,862	For
ProShares	9,135	For
Goldman Sachs	7,909	For
SEI	7,500	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

7. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 34,369,582AGAINST: 124,022

CABALETTA BIO INC.’s own tally for this item (“The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, recommended for ratification in Propos”): 34,369,582 for, 124,022 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,743,101 outstanding shares: 68% for, 0.3% against (68% of the company cast a for/against vote).

The 36 asset managers below cast 99.9% of the shares they voted on this item FOR (7,042,019 for, 184 against).

FOR 99.9%

FOR: 7,042,019 (100.0%)AGAINST: 184 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at CABALETTA BIO INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	1,930,685	For
Vanguard	1,767,721	For
BlackRock	905,056	For
Prudential/PGIM	902,204	For
Fidelity	409,339	For
Federated Hermes	321,176	For
Charles Schwab	159,866	For
Equitable	152,199	For
Thrivent	92,880	For
QUANTITATIVE MASTER SERIES LLC	64,117	For
TIAA	39,686	For
Northern Trust	36,626	For
Lincoln Financial	34,200	For
AIG/SunAmerica	31,471	For
Global X	26,547	For
Pacific Life	22,121	For
Nationwide	21,929	For
John Hancock	20,425	For
MASTER INVESTMENT PORTFOLIO	18,345	For
Bridge Builder Trust	17,014	For
Blackstone Alternative Investment Funds	11,200	For
BRIDGEWAY FUNDS INC	10,862	For
ProShares	9,135	For
Goldman Sachs	7,909	For
SEI	7,500	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

8. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

ABSTAIN 99.3%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ABSTAIN: 3,484,473 (99.4%)ONE YEAR: 21,069 (0.6%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at CABALETTA BIO INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	0	3,484,473	0	Abstain
JPMorgan	0	0	0	0	One Year

Largest CABALETTA BIO INC. shareholders voting in 2024-2025

Ranked by the number of CABALETTA BIO INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 50,743,101 shares outstanding at the time of that meeting.

Top CABALETTA BIO INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	T. Rowe Price	11.76%
2	Bain Capital Life Sciences Investors, LLC	5.44%
3	BlackRock	4.25%
4	JENNISON ASSOCIATES LLC	3.64%
5	Vanguard	3.62%
6	ADAGE CAPITAL PARTNERS GP, L.L.C.	3.43%
7	Prudential/PGIM	1.78%
8	Federated Hermes	1.30%
9	GEODE CAPITAL MANAGEMENT, LLC	1.06%
10	State Street	0.90%

Reported CABALETTA BIO INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

CABALETTA BIO INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Jennison Associates LLC	47.83%	13G
PRUDENTIAL FINANCIAL INC	47.83%	13G
Cormorant Asset Management, LP	20.69%	13G
Bain Capital Life Sciences Opportunities III, LP	19.07%	13G
Millennium Management LLC	10.11%	13G
Citadel Advisors LLC	9.24%	13G
Alyeska Investment Group, L.P.	8.87%	13G
BlackRock	6.80%	13F
Kenneth Griffin	6.21%	13G
Nichtberger Steven	5.98%	13G

Percentages above are of 50,743,101 shares outstanding, as reported by CABALETTA BIO INC. on its Form 10-Q dated 2025-05-09 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CABALETTA BIO INC.’s 10-Q dated 2025-05-09. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At CABALETTA BIO INC.'s shareholder meeting held 2025-06-09, in the 2024-2025 proxy season, 104 asset managers reported how they voted in their SEC Form N-PX filings, covering 980 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — FOR was 54.2% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: CABALETTA BIO INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-10.

CABALETTA BIO INC. proxy season coverage: 2024-2025 (this page).